{
  "society": "AISF",
  "version": "2024",
  "publication_date": "2024-11-01",
  "title": "AISF position paper on MASLD",
  "status": "published",
  "recommendations": [
    {"recommendation_id": "AISF-2024-R01", "topic": "definition", "text_en": "AISF endorses MASLD nomenclature.", "text_kr_summary": "AISF MASLD 채택.", "strength": "strong", "evidence_grade": "B", "cite_pmids": ["37363821"], "related_nits": [], "related_drugs": []},
    {"recommendation_id": "AISF-2024-R02", "topic": "screening", "text_en": "Italian primary care: FIB-4 first then VCTE.", "text_kr_summary": "FIB-4 first then VCTE.", "strength": "strong", "evidence_grade": "B", "cite_pmids": ["33271056"], "related_nits": ["FIB-4", "LSM"], "related_drugs": []},
    {"recommendation_id": "AISF-2024-R03", "topic": "fib4_cutoff", "text_en": "FIB-4 1.3/2.67 endorsed.", "text_kr_summary": "FIB-4 1.3/2.67.", "strength": "strong", "evidence_grade": "B", "cite_pmids": ["17326139"], "related_nits": ["FIB-4"], "related_drugs": []},
    {"recommendation_id": "AISF-2024-R04", "topic": "resmetirom", "text_en": "Resmetirom: awaits EMA decision; consider trial enrollment.", "text_kr_summary": "EMA 결정 전, 임상시험 권고.", "strength": "weak", "evidence_grade": "C", "cite_pmids": ["38324483"], "related_nits": [], "related_drugs": ["resmetirom"]},
    {"recommendation_id": "AISF-2024-R05", "topic": "weight_loss", "text_en": "Mediterranean diet emphasized; weight loss 7-10%.", "text_kr_summary": "지중해식, 7-10% 감량.", "strength": "strong", "evidence_grade": "A", "cite_pmids": ["25865049"], "related_nits": [], "related_drugs": []}
  ]
}